Demand For Serotonin-Norepinephrine Reuptake Inhibitors (Snris), Is Set To Increase At A CAGR Of 2% Across The Assessment Period Of 2021 To 2031
The depression drugs market, valued at over US$ 6.5 billion in 2017, is likely to witness bearishness in the near future, with a new report [read full press release…]